MarketCap
Facebook
X
Telegram
TFF Pharmaceuticals Total Non Current Liabilities | TFFP
Annual Total Non Current Liabilities TFF Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 1.13 M | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.13 M | 1.13 M | 1.13 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Galectin Therapeutics
GALT
|
52 K | $ 3.29 | -2.66 % | $ 210 M |  USA |
 |
Corcept Therapeutics Incorporated
CORT
|
22.8 M | $ 74.57 | 1.66 % | $ 7.74 B | USA |
 |
Progenity, Inc.
PROG
|
189 M | - | -3.47 % | $ 164 M | USA |
 |
Strongbridge Biopharma plc
SBBP
|
34.4 M | - | 1.52 % | $ 136 M | USA |
 |
Innate Pharma S.A.
IPHA
|
47.8 M | $ 1.59 | 3.25 % | $ 142 M |  France |
 |
Seneca Biopharma, Inc.
SNCA
|
233 K | - | -1.19 % | $ 28.7 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
748 M | $ 58.33 | 2.1 % | $ 11.2 B | USA |
 |
Matinas BioPharma Holdings
MTNB
|
915 K | $ 0.88 | -29.93 % | $ 4.82 M | USA |
 |
Enanta Pharmaceuticals
ENTA
|
4.73 M | $ 11.61 | 3.46 % | $ 248 K | USA |
 |
Milestone Pharmaceuticals
MIST
|
696 K | $ 0.68 | 2.4 % | $ 72.2 M |  Canada |
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
56.8 M | $ 95.42 | 0.42 % | $ 7.08 B | USA |
 |
Lipocine
LPCN
|
230 K | $ 1.59 | -0.31 % | $ 8.66 M | USA |
 |
PTC Therapeutics
PTCT
|
2.14 B | $ 64.91 | 1.2 % | $ 5.16 B | USA |
 |
Seres Therapeutics
MCRB
|
74.7 M | $ 1.51 | -3.21 % | $ 13.4 M | USA |
 |
Madrigal Pharmaceuticals
MDGL
|
347 M | $ 432.77 | 0.04 % | $ 9.71 B | USA |
 |
CEL-SCI Corporation
CVM
|
19.5 M | $ 1.31 | -7.09 % | $ 10.5 M | USA |
 |
Inventiva S.A.
IVA
|
105 M | $ 4.01 | 1.65 % | $ 240 M | France |
 |
MeiraGTx Holdings plc
MGTX
|
83.9 M | $ 9.68 | 0.57 % | $ 779 M | USA |
 |
Processa Pharmaceuticals
PCSA
|
1.05 M | $ 1.85 | -1.07 % | $ 2.42 M | USA |
 |
Eton Pharmaceuticals
ETON
|
27.5 M | $ 68.4 | 1.27 % | $ 1.84 B | USA |
 |
IDEAYA Biosciences
IDYA
|
27.6 M | $ 32.71 | 3.02 % | $ 2.89 B | USA |
 |
Protalix BioTherapeutics
PLX
|
7.6 M | $ 3.13 | 9.44 % | $ 246 M |  Israel |
 |
Lantern Pharma
LTRN
|
108 K | $ 0.47 | 1.53 % | $ 5.12 M | USA |
|
Foghorn Therapeutics
FHTX
|
247 M | $ 2.04 | 7.37 % | $ 128 M | USA |
 |
Ocugen
OCGN
|
32.6 M | $ 0.96 | 0.8 % | $ 300 M | USA |
 |
Oncolytics Biotech
ONCY
|
6.88 M | $ 0.42 | 9.19 % | $ 40.3 M | Canada |
 |
Minerva Neurosciences
NERV
|
231 M | $ 2.56 | 2.81 % | $ 21.7 M | USA |
 |
Kamada Ltd.
KMDA
|
62.2 M | $ 8.1 | 0.43 % | $ 467 M | Israel |
 |
Neurocrine Biosciences
NBIX
|
635 M | $ 173.86 | 2.79 % | $ 17.3 B | USA |
 |
Nanobiotix S.A.
NBTX
|
94.7 M | $ 32.73 | 0.03 % | $ 1.57 T | France |
 |
Mereo BioPharma Group plc
MREO
|
1.53 M | $ 0.31 | 2.89 % | $ 247 M |  Britain |
 |
Maravai LifeSciences Holdings
MRVI
|
353 M | $ 7.71 | -1.91 % | $ 1.11 B | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
56.6 M | $ 1.86 | 1.34 % | $ 675 M | USA |
 |
Moleculin Biotech
MBRX
|
8.35 M | $ 8.05 | -0.12 % | $ 9.54 M | USA |
 |
Nurix Therapeutics
NRIX
|
61.5 M | $ 16.46 | 3.65 % | $ 1.43 B | USA |
 |
Nkarta
NKTX
|
69.6 M | $ 1.49 | 10.0 % | $ 110 M | USA |
 |
MacroGenics
MGNX
|
36.7 M | $ 2.33 | -3.85 % | $ 147 M | USA |
 |
Protagonist Therapeutics
PTGX
|
8.04 M | $ 134.78 | -1.06 % | $ 8.57 B | USA |
|
Nuvation Bio
NUVB
|
207 M | $ 4.3 | 2.26 % | $ 1.47 B | USA |
 |
Novo Nordisk A/S
NVO
|
133 B | $ 41.06 | 0.88 % | $ 182 B |  Danmark |
 |
Marker Therapeutics
MRKR
|
7.04 M | $ 0.95 | 0.07 % | $ 14.5 M | USA |
 |
NextCure
NXTC
|
4.06 M | $ 6.3 | 5.35 % | $ 33.5 M | USA |
 |
Rocket Pharmaceuticals
RCKT
|
46.5 M | $ 2.47 | 0.82 % | $ 274 M | USA |
 |
PMV Pharmaceuticals
PMVP
|
435 K | $ 1.25 | 2.87 % | $ 65.7 M | USA |
 |
Olema Pharmaceuticals
OLMA
|
3.07 M | $ 8.16 | 12.24 % | $ 710 M | USA |
 |
Kymera Therapeutics
KYMR
|
79.9 M | $ 135.02 | -1.19 % | $ 11.4 B | USA |
 |
Oragenics
OGEN
|
152 K | $ 0.35 | 1.4 % | $ 755 K | USA |
 |
Ovid Therapeutics
OVID
|
12 M | $ 2.77 | -1.07 % | $ 361 M | USA |
 |
Passage Bio
PASG
|
20.4 M | $ 3.91 | 3.44 % | $ 12.5 M | USA |